ALK and non-small cell lung carcinoma: For example, asexual lymphoma kinase (ALK) PROTACs have been shown to overcome resistance to ALK inhibitors (such as alectinib, ceritinib, and brigatinib) during the treatment of non-small cell lung cancer.26–28